Fig. 7
Effect of MAPKK inhibition on the Nrf2 activation pathway in HUVECs pretreated for 24 h with AS or FS and then exposed for 24 h to 32 % O2 (mild hyperoxic conditions) or to 21 % O2 (normoxic conditions), as evaluated by Western blot analysis. Cells were incubated with the pharmacological MAPKK inhibitor PD98059 (25 μM) for 1 h before AS or FS addition. Cultures treated with FS and exposed to normoxic conditions were used as negative controls. Each point represents mean ± SD of three experiments. The figure shows a representative image from three independent experiments. Results by densitometry are reported as fold change against controls and expressed as mean ± SD of three experiments. Nrf2 bands intensity values were normalized to the corresponding Lamin B values. *P < 0.05 versus FS-treated cells exposed to normoxic conditions. °P < 0.05 versus FS-treated cells exposed to hyperoxic conditions. @ P < 0.05 versus FS-treated cells exposed to hyperoxic conditions and treated with PD98059. § P < 0.05 versus AS-treated cells exposed to normoxic conditions. # P < 0.05 versus AS-treated cells exposed to hyperoxic conditions. ^ P < 0.05 versus AS-treated cells exposed to hyperoxic conditions and treated with PD98059. AS, human serum obtained after Medox® capsules consumption; FS, human serum obtained immediately before Medox® capsules consumption